Although this has previously been shown to have remarkable success in preclinical tumor models, the virus-mediated expression of the designer cytokine hyper-IL-6 offered a new approach to significantly reduce the duration of thrombocytopenia, a serious side effect of chemotherapy. This evidence concerns the gene IL6 and neoplasm.